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This article presents the incidence of hospital-acquired pneumonia (HAP) in Portugal
during a four-year period (2014e2017). Data were retrieved from the 100 Portuguese
hospital diagnosis discharge database for adult patients and included gender, age, chronic
comorbidities, mortality and hospital length of stay. There were 28,632 episodes of HAP,
an incidence of 0.95 per 100 admissions. HAP patients had both a prolonged hospital length
of stay (mean 26.4 days) and high mortality (33.6%). Most episodes occurred in patients
aged 65 years and in males (76.1% and 61.7%, respectively). Invasive ventilation was
required in 18.8%.
ª 2021 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.Introduction
Hospital-acquired infections, especially pneumonia (HAP),
remain one of the most important challenges clinicians face in
everyday work [1]. Nevertheless, the epidemiology of HAP isent of Intensive Care,
ima Costa, N2, 2600-009,
263006500; fax: þ351
hvfx.pt (J. Gonçalves-
ociety. Published by Elsevieruncertain. Epidemiological studies focusing on HAP in non-
ventilated patients suggest that the incidence may be twice
as high as that of ventilator-associated pneumonia, with similar
mortality rate and frequently leading to intensive care unit
(ICU) admission [2,3].
There is scarce information regarding both HAP risk and
incidence outside the ICU, and epidemiological data regarding
HAP global incidence is clearly needed.
This study addressed the incidence of HAP at a national
level. Data from four consecutive years (2014e2017) were
studied to account for possible seasonal variation. We included
all hospitals, both community and university, of the PortugueseLtd. All rights reserved.
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burden of HAP nationally, and to identify the subgroups at
higher risk.
Methods
The Central Administration of the Health System of the
Portuguese Ministry of Health records administrative and clin-
ical discharge data for all admissions to the 100 (77 general)
National Health System hospitals in mainland Portugal. The
anonymized database includes all discharge diagnoses of hos-
pital inpatients, either dead or alive, codified according to the
International Classification of Diseases, 9th Revision Clinical
Modification (ICD-9-CM), until 2016, and the 10th Revision (ICD-
10-CM), from 2017 onwards. The ICD-9 and ICD-10 codes used to
identify the different pathologies for this study are described
in detail in Supplementary Appendix A.
In 2014 a complementary codification approach was intro-
duced in Portugal. All diagnoses were coded according to their
presence or absence on admission. Pneumonia not ‘present on
admission’ is, by definition, acquired in the hospital. Con-
sequently, this codification allowed an easier and more accu-
rate identification of HAP episodes.
We retrospectively analysed data from all adult patients
discharged between January 1st, 2014, and December 31st,
2017, with HAP, that is a pneumonia ‘not present on admis-
sion’. Patients aged <18 years or with a hospital length of stay
(LOS) of <48 h were excluded. Administrative data were col-
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Figure 1. Incidence of hospital-acquired pneumonia for females (d
acquired pneumonia increased almost five times with age, mainly
although the incidence was twice as high in males (OR: 2.05; 95% CI:comorbidities, acute stroke, type of admission (either medical
or for a surgical procedure) or ICU admission, along with out-
comes, especially mortality, invasive mechanical ventilation,
and hospital LOS.
A descriptive statistical analysis approach was adopted.
Rates of HAP per 100 episodes of hospitalization and per 1000
hospital patient-days (with 95% confidence intervals (CIs)),
according to age and gender, were computed for the whole
population, for each year of the study and for the relevant
subgroups.
Continuous variables were expressed as mean  square
deviation and/or median (interquartile range) according to
data distribution; the discrete variables were expressed as
total number (percentage).
The statistical significance analysis was performed using the
c2-test (for discrete variables), Student’s t-test,
ManneWhitney test, or KolmogoroveSmirnov test (for con-
tinuous variables), according to data distribution. Odds ratios
(ORs) with 95% CI were computed.
All the calculations presented were obtained using the
statistical software package R statistical computing environ-
ment (R Core Team 2020, R Foundation for Statistical Com-
puting, Vienna, Austria) and the Microsoft Excel spreadsheet
(Microsoft Corp., Redmond, WA, USA).
This study was approved by the Central Administration of
the Portuguese National Health System. As all individual
patient information was protected and only aggregated data
were available, the requirement for patient informed consent
was waived.55–59 60–64 65–69 70–74 75–79 80–84 85+
 (years)
otted line) and males (dashed line). The incidence of hospital-
after 70 years. The curve trend was similar for both genders,
2.0e2.1; P < 0.001).
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Hospital-acquired pneumonia incidence
A total of 3,026,233 hospital discharges were evaluated. We
identified 28,632 episodes of HAP. The overall incidence was
0.95% and this increased almost five times with age (Figure 1).
The incidence of HAP per 1000 hospital-days was 1.13 (1.42 in
men and 0.85 in women). Male patients represented only 42.3%
of all hospital admissions but accounted for 61.9% of HAP cases
(Figure 1).
Overall, HAP was strongly associated with prolonged LOS
(mean 26.4 days) and with very high mortality (33.6%), both
significantly above the recorded values for general hospital-
izations of 48 h (mean LOS: 8.4 days; mortality rate 6.7%; P <
0.0001). Mortality of patients with HAP also increased with age,
attaining 40.1% in patients aged >85 years. Even in patients
aged <30 years, mortality was still 12.4%.
The incidence of HAP was higher in patients admitted for a
medical reason (1.1% vs 0.69% of surgical admissions, P <
0.0001). As many as 5383 (12.5%) of all patients ventilated in
mainland Portugal during the study period had HAP, either
before or as a complication of invasive mechanical ventilation,
unveiling a significant burden of HAP in intensive care medi-
cine. Again, these patients had a high mortality rate (42%) and
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Figure 2. Association of acute stroke and hospital-acquired pneum
association between age and the presence of stroke in patients with h
acquired pneumonia in all patients with stroke increased roughly 1.05
two time-points).Comorbidities and hospital-acquired pneumonia
Mortality was consistently higher in patients with HAP and
chronic diseases, especially chronic hepatic disease (44.2%).
Moreover, mortality rate increased with the cumulative num-
ber of comorbidities, from 29.1% in patients without any
diagnosed comorbidity to 40.8% in patients with two or more
(mortality OR for 1 comorbidity: 1.48; 95% CI: 1.33e1.65).
Acute stroke was strongly associated with HAP (Figure 2).
The overall stroke prevalence in HAP patients was 14.3% (with
no significant gender difference), well above the reported
3.24% stroke prevalence for the general hospitalizations48 h.
This association increased with age, roughly 1% per each five
years, being 17.3% in patients aged >85 years, whereas only 6%
of all hospitalizations in the same age group had a diagnosis of
stroke. Stroke patients (either ischaemic or haemorrhagic) who
developed HAP during their hospital stay had a much higher risk
of death (OR: 4.84; 95% CI: 4.53e5.16).
Discussion
The incidence of HAP in mainland Portugal during a con-
secutive four-year period, from 2014 to 2017, was 0.95%, which
corresponded to 1.13 episodes per 1000 hospital-days. Patients
aged 65 years and male gender were significantly more prone
to HAP, especially patients with an acute stroke. Hospital55–59 60–64 65–69 70–74 75–79 80–84 85+
(years)
onia for females (dotted line) and males (dashed line). A close
ospital-acquired pneumonia was noted. The incidence of hospital-
% per every five years of age (P < 0.001 for comparisons between
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with age. Even patients without significant comorbidities had a
mortality rate of roughly 30%, suggesting that attributable
mortality may be substantial. Hospital LOS was very long (26.4
days), roughly three times higher than that of the general
population. Invasive mechanical ventilation was provided to
18.8% of these patients.
An important limitation of retrospective studies addressing
HAP is the reliance on clinical diagnoses, especially as two-
thirds of HAP may be acquired outside of the ICU, where
classic signs of pneumonia may be missing in as many as half of
the patients [4e6]. Automatic detection of HAP patients,
based on oxygenation fall and antibiotic use, has recently been
proposed and may facilitate identification [7].
As a consequence, the reported incidence of HAP seems to
be mostly related to the definitions used to identify the cases
and the included population. In a recently published European
point prevalence study an overall incidence of 1.3% was noted
and a Portuguese HAP incidence of 2.7% was reported, much
higher than we found in our study [3]. Hospital selection bias
and a possible seasonal variation may help to explain these
differences.
A large study from the USA, including more than six million
patients, reported an HAP incidence of 1.6%, corresponding to
3.63 per 1000 hospital-days, again higher than our rates [8]. In
that study, HAP was defined as a discharge secondary diagnosis
of pneumonia, whereas we only included patients with pneu-
monia considered to be ‘not present on admission’ [8]. By
contrast, a study done in 24 hospitals, using an HAP definition
identical to ours, reported an incidence of 0.12e2.28 per 1000
hospital-days, very similar to that in our study [4]. In the same
study, LOS was also very long and 37.3% of HAP patients stayed
in the hospital for >20 days [4].
The impact of HAP on outcome also seems to extend to the
ICU. In a large cohort of ICU patients, the incidence of HAP was
5% in ventilated patients and 2% in non-ventilated patients. The
30-day mortality was significantly increased in both groups
(adjusted hazard ratio: 1.38 (1.24e1.52) in ventilated and 1.82
(1.35e2.45) in non-ventilated) [9].
In the current study, age was the most important predictor
of HAP and >75% of HAP occurred in patients aged >65 years,
revealing an association between this pathology, senescence,
and frailty. Along with age, acute stroke may cause swallowing
dysfunction and facilitate aspiration, both as a result of direct
neurologic insult or as a consequence of oropharyngeal muscle
weakness [10]. In our study, an interaction of age and acute
stroke on the incidence of HAP was disclosed (Figure 2).
This study has some limitations. It relates only to Portuguese
hospitals, it relies on a discharge diagnosis codification system,
it is retrospective, and limitations of the database do not allow
segregation of ventilator-associated HAP. Furthermore, the
anonymized nature of the database did not allow us to perform
discharge diagnosis audits to further validate the data. It also
has several strengths. To our knowledge, it is the first HAP
incidence study done at a national level, including both large
and small community as well as teaching hospitals. In addition,
it includes data from four complete consecutive years,
accounting for a potential seasonal variation. A large database
(including more than three million hospital admissions) was
evaluated, which strengthens our conclusions.
In conclusion, HAP is common in hospital wards as well as in
the ICU, and its incidence increased with age, male gender, andstroke. It is associated with significant mortality, hospital LOS,
and healthcare resource utilization. The strong association
with stroke deserves further study.
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